WILMINGTON, MA — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, recently announced that John Fletcher has signed on as a strategic advisor to the company’s senior management. Fletcher is the founder and leader of healthcare consulting and venture capital activities at Fletcher Spaght, a strategy consulting firm focused on revenue growth and future growth potential.
“At this point in the growth and progress of MMS, when our flagship product, MicroStent, is soon to enter its first clinical trial, we are so pleased to welcome John Fletcher from Fletcher Spaght as an advisor to our team,” said Micro Medical Solutions CEO Gregory Sullivan. “John has decades of experience and insights into developing effective growth solutions for healthcare companies, including devices for cardiovascular and endovascular disease. We’re excited to draw on his knowledge as we advance our goals at MMS.”
Fletcher brings more than 35 years of healthcare and medical device experience to MMS. He currently serves as CEO and managing director of Fletcher Spaght Inc, a strategy consulting and venture capital firm that he founded in 1983. Prior to founding Fletcher Spaght, he was Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and other high-technology industries.
Fletcher joined the Board of Directors of publicly traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. During his 15-year tenure on the board, Spectranetics expanded its therapeutic platforms and generated significant commercial growth. In August 2017, Spectranetics was acquired by Royal Philips in a transaction valued at $2.2 billion. Fletcher was named 2019 Director of the Year by the National Association of Corporate Directors (NACD) for his work at Spectranetics.
“Micro Medical Solutions’ MicroStent device has already demonstrated exciting value for patients with peripheral artery disease facing the devastation of below-the-knee amputations,” Fletcher said. “As the approval process for this technology moves ahead, I am looking forward to helping the company’s high-level team bring MicroStent to patients in the USA and develop effective strategies for the future.”
Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions and is Chairman of Metabolon. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. He was an instructor for courses in international business and a Ph.D. Candidate at the Wharton School of the University of Pennsylvania. Fletcher served as a Captain and jet pilot in the United States Air Force.
(NOTE: The above press release is from Micro Medical Solutions via PR Newswire.)
Like Wilmington Apple on Facebook. Follow Wilmington Apple on Twitter. Follow Wilmington Apple on Instagram. Subscribe to Wilmington Apple’s daily email newsletter HERE. Got a comment, question, photo, press release, or news tip? Email firstname.lastname@example.org.